Posts filed under ‘Desinfection and Sterilization’

Letter – Stability of SARS-CoV-2 in different environmental conditions

LANCET April 2, 2020

Anteriormente informamos la detección del SARS-CoV-2 en diferentes muestras clínicas.

Este coronavirus se puede detectar en diferentes superficies en un sitio contaminado.

Aquí, informan la estabilidad del SARS-CoV-2 en diferentes condiciones ambientales.

PDF

https://www.thelancet.com/action/showPdf?pii=S2666-5247%2820%2930003-3

April 4, 2020 at 11:56 am

Letter – Stability of SARS-CoV-2 in different environmental conditions.

LANCET April 2, 2020

Anteriormente informamos la detección del SARS-CoV-2 en diferentes muestras clínicas.

Este coronavirus se puede detectar en diferentes superficies en un sitio contaminado.

Aquí, informan la estabilidad del SARS-CoV-2 en diferentes condiciones ambientales.

PDF

https://www.thelancet.com/action/showPdf?pii=S2666-5247%2820%2930003-3

 

April 4, 2020 at 11:30 am

REVIEW – Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents.

J Hospital Infect. March 2020 V.104 N.3 P.246–251.

Kampf G,Todt D, Pfaender S, Steinmann E.

Actualmente, la aparición de un nuevo coronavirus humano, SARS-CoV-2, se ha convertido en un problema de salud global que causa infecciones graves del tracto respiratorio en humanos.

Las transmisiones de persona a persona se han descrito con tiempos de incubación de entre 2 y 10 días, lo que facilita su propagación a través de gotas, manos o superficies contaminadas.

Por lo tanto, revisaron la literatura sobre toda la información disponible sobre la persistencia de coronavirus humanos y veterinarios en superficies inanimadas, así como las estrategias de inactivación con agentes biocidas utilizados para la desinfección química, p. ej. en instalaciones sanitarias.

El análisis de 22 estudios revela que los coronavirus humanos como el coronavirus del Síndrome Respiratorio Agudo Severo (SARS), el coronavirus del Síndrome Respiratorio del Medio Oriente (MERS) o los coronavirus humanos endémicos (HCoV) pueden persistir en superficies inanimadas como metal, vidrio o plástico por hasta 9 días, pero se puede inactivar eficientemente mediante procedimientos de desinfección de superficie con:

etanol al 62–71%,

peróxido de hidrógeno al 0.5% o

hipoclorito de sodio al 0.1% en 1 minuto.

Otros agentes biocidas como el cloruro de benzalconio al 0.05–0.2% o el digluconato de clorhexidina al 0.02% son menos efectivos.

Como no hay terapias específicas disponibles para el SARS-CoV-2, la contención temprana y la prevención de una mayor propagación serán cruciales para detener el brote en curso y controlar este nueva infección.

FULL TEXT

https://www.journalofhospitalinfection.com/article/S0195-6701(20)30046-3/fulltext

PDF (CLIC en PDF)

 

April 4, 2020 at 10:34 am

COVID-19 Illness in Native and Immunosuppressed States – A Clinical-Therapeutic Staging Proposal

Journal of Heart and Lung Transplantation March 2020

Hasan K. Siddiqi MD, MSCR , Mandeep R. Mehra MD, MSc

The onslaught of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated coronavirus disease 2019 (COVID-19) has gripped the world in a pandemic and challenged the culture, economy and healthcare infrastructure of its population. It has become increasingly important that health systems and their clinicians adopt a universal consolidated framework to recognize the staged progression of COVID-19 illness in order to deploy and investigate targeted therapy likely to save lives. The largest report of COVID-19 from the Chinese Centers for Disease Control and Prevention summarized findings from 72, 314 cases and noted that while 81% were of a mild nature with an overall case fatality rate of 2.3%, a small sub-group of 5% presented with respiratory failure, septic shock and multi-organ dysfunction resulting in fatality in half of such cases, a finding that suggests that it is within this group that the opportunity for life saving measures may be most pertinent….

FULL TEXT

https://www.jhltonline.org/article/S1053-2498(20)31473-X/fulltext?mobileUi=0

PDF

https://www.jhltonline.org/article/S1053-2498(20)31473-X/pdf

 

March 29, 2020 at 10:58 am

Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents

Journal of Hospital Infection March 2020 V.104 P.246-251

Kampf a, *, D. Todt b, S. Pfaender b, E. Steinmann b

a University Medicine Greifswald, Institute for Hygiene and Environmental Medicine, Ferdinand-Sauerbruch-Straße, 17475

Greifswald, Germany

b Department of Molecular and Medical Virology, Ruhr University Bochum, Universita¨tsstrasse 50, 44801 Bochum, Germany

Currently, the emergence of a novel human coronavirus, SARS-CoV-2, has become a global health concern causing severe respiratory tract infections in humans. Human-to-human transmissions have been described with incubation times between 2-10 days, facilitating its spread via droplets, contaminated hands or surfaces. We therefore reviewed the literature on all available information about the persistence of human and veterinary coronaviruses on inanimate surfaces as well as inactivation strategies with biocidal agents used for chemical disinfection, e.g. in healthcare facilities. The analysis of 22 studies reveals that human coronaviruses such as Severe Acute Respiratory Syndrome (SARS) coronavirus, Middle East Respiratory Syndrome (MERS) coronavirus or endemic human coronaviruses (HCoV) can persist on inanimate surfaces like metal, glass or plastic for up to 9 days, but can be efficiently inactivated by surface disinfection procedures with 62e71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite within 1 minute. Other biocidal agents such as 0.05e0.2% benzalkonium chloride or 0.02% chlorhexidine digluconate are less effective. As no specific therapies are available for SARS-CoV-2, early

containment and prevention of further spread will be crucial to stop the ongoing outbreak and to control this novel infectious thread.

FULL TEXT

https://www.journalofhospitalinfection.com/article/S0195-6701(20)30046-3/fulltext

PDF

https://www.journalofhospitalinfection.com/article/S0195-6701(20)30046-3/pdf

March 29, 2020 at 10:29 am

CORRESPONDENCE – Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

N Engl J of Medic March 17, 2020

A novel human coronavirus that is now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (formerly called HCoV-19) emerged in Wuhan, China, in late 2019 and is now causing a pandemic.1 We analyzed the aerosol and surface stability of SARS-CoV-2 and compared it with SARS-CoV-1, the most closely related human coronavirus….

FULL TEXT

https://www.nejm.org/doi/full/10.1056/NEJMc2004973?query=RP

PDF

https://www.nejm.org/doi/pdf/10.1056/NEJMc2004973

March 29, 2020 at 10:26 am

Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019

Morbidity and Mortality Weekly Report (MMWR) (CDC) January 10, 2020 V.69 N.1 P-6-9

What is already known about this topic?

Candida auris is an emerging yeast that is often drug-resistant.

What is added by this report?

Three chronically ill patients in New York were identified as having pan-resistant C. auris after receipt of antifungal medications. No transmission of the pan-resistant isolates was found in patient contacts or the facility environments.

What are the implications for public health practice?

Three years after the first identification of C. auris in New York, pan-resistant isolates remain rare. Continued surveillance for C. auris, prudent antifungal use, and susceptibility testing for all C. auris clinical isolates (especially after patients have been treated with antifungal drugs) are needed.

Candida auris is a globally emerging yeast that causes outbreaks in health care settings and is often resistant to one or more classes of antifungal medications (1). Cases of C. auris with resistance to all three classes of commonly prescribed antifungal drugs (pan-resistance) have been reported in multiple countries (1). C. auris has been identified in the United States since 2016; the largest number (427 of 911 [47%]) of confirmed clinical cases reported as of October 31, 2019, have been reported in New York, where C. auris was first detected in July 2016 (1,2). As of June 28, 2019, a total of 801 patients with…..

FULL TEXT

https://www.cdc.gov/mmwr/volumes/69/wr/mm6901a2.htm?s_cid=mm6901a2_w&deliveryName=USCDC_921-DM16734

PDF

https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6901a2-H.pdf

January 9, 2020 at 3:22 pm

Older Posts


Calendar

April 2020
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  

Posts by Month

Posts by Category